Gullestad, Lars

Rosuvastatin in older patients with systolic heart failure

Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine

Lipoproteins and Cardiovascular HealthHeart Failure Treatment and Management

Cited by 1,487

Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure: The Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

Hjalmarson, Å., Goldstein, S., Fagerberg, B., Wedel, H., Waagstein, F., Kjekshus, J., Wikstrand, J., El Allaf, D., Vítovec, J., Aldershvile, J., et al. (2000) · JAMA

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,399

Microbiota‐dependent metabolite trimethylamine‐N‐oxide is associated with disease severity and survival of patients with chronic heart failure

Trøseid, M., Ueland, T., Hov, J. R., Svardal, A., Gregersen, I., Dahl, C. P., Aakhus, S., Gude, E., Bjørndal, B., Halvorsen, B., et al. (2015) · Journal of Internal Medicine

Gut microbiota and healthHeart Failure Treatment and Management

Cited by 464

Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-Dinet, M., Bhatt, D. L., Bittner, V. A., Budaj, A. J., Diaz, R., Goodman, S. G., Hanotin, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 315

Systemic inflammation in heart failure – The whys and wherefores

Yndestad, A., Kristian Damås, J., Øie, E., Ueland, T., Gullestad, L., & Aukrust, P. (2006) · Heart Failure Reviews

Cardiac Fibrosis and RemodelingHeart Failure Treatment and Management

Cited by 294

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 217

Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial

Bhatt, D. L., Steg, P. G., Mehta, S. R., Leiter, L. A., Simon, T., Fox, K., Held, C., Andersson, M., Himmelmann, A., Ridderstråle, W., et al. (2019) · The Lancet

Antiplatelet Therapy and Cardiovascular DiseasesCoronary Interventions and Diagnostics

Cited by 209

Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol

Schwartz, G. G., Szarek, M., Bittner, V. A., Diaz, R., Goodman, S. G., Jukema, J. W., Landmesser, U., López-Jaramillo, P., Manvelian, G., Pordy, R., et al. (2021) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 150

Effect of Rosuvastatin on Repeat Heart Failure Hospitalizations

Rogers, J. K., Jhund, P. S., Perez, A.-C., Böhm, M., Cleland, J. G., Gullestad, L., Kjekshus, J., van Veldhuisen, D. J., Wikstrand, J., Wedel, H., et al. (2014) · JACC: Heart Failure

Heart Failure Treatment and ManagementLipoproteins and Cardiovascular Health

Cited by 138

Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

Hagström, E., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Danchin, N., Diaz, R., Goodman, S. G., Harrington, R. A., Jukema, J. W., et al. (2022) · Circulation

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 118

Effect of High-Intensity Interval Training in De Novo Heart Transplant Recipients in Scandinavia: One-Year Follow-Up of the HITTS Randomized, Controlled Study

Nytrøen, K., Rolid, K., Andreassen, A. K., Yardley, M., Gude, E., Dahle, D. O., Bjørkelund, E., Relbo Authen, A., Grov, I., Philip Wigh, J., et al. (2019) · Circulation

Cardiovascular and exercise physiologyTransplantation: Methods and Outcomes

Cited by 80

Prevalence, risk factors, and type of sleep apnea in patients with paroxysmal atrial fibrillation

Traaen, G. M., Øverland, B., Aakerøy, L., Hunt, T. E., Bendz, C., Sande, L., Aakhus, S., Zaré, H., Steinshamn, S., Anfinsen, O. G., et al. (2020) · IJC Heart & Vasculature

Obstructive Sleep Apnea ResearchAtrial Fibrillation Management and Outcomes

Cited by 71

Inflammation and chronic heart failure–potential therapeutic role of intravenous immunoglobulin

Aukrust, P., Yndestad, A., Damås, J. K., & Gullestad, L. (2004) · Autoimmunity Reviews

Cardiac Fibrosis and RemodelingHeart Failure Treatment and Management

Cited by 37

Effect of atorvastatin on muscle symptoms in coronary heart disease patients with self-perceived statin muscle side effects: a randomized, double-blinded crossover trial

Kristiansen, O., Vethe, N. T., Peersen, K., Wang Fagerland, M., Sverre, E., Prunés Jensen, E., Lindberg, M., Gjertsen, E., Gullestad, L., Perk, J., et al. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy

Lipoproteins and Cardiovascular HealthPharmacovigilance and Adverse Drug Reactions

Cited by 27

YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in Aortic Stenosis

Arain, F., Abraityte, A., Bogdanova, M., Solberg, O. G., Michelsen, A. E., Lekva, T., Aakhus, S., Holm, S., Halvorsen, B., Finsen, A. V., et al. (2020) · Circulation: Heart Failure

Cardiac Valve Diseases and TreatmentsAortic Disease and Treatment Approaches

Cited by 13